5PSQ-027 Early real-world effectiveness and safety of secukinumab in patients with psoriasis

BACKGROUND: Secukinumab is a recently approved interleukin 17A inhibitor indicated for the treatment of patients with plaque psoriasis, psoriatic arthritis and ankylosing spondylarthritis. PURPOSE: The aim of the study was to assess the early effectiveness and safety of secukinumab in patients with...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Eur J Hosp Pharm
Huvudupphovsmän: Ortiz, M, Torres, P Rovira, Zamora, M Gomez, Manzanares, M Castro, Esterlich, MM Santandreu, Alomar, C Perello, Sanchez, O Delgado, Lobon, A Gomez
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Group 2018
Ämnen:
Section 5: Patient safety and quality assurance
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535515/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.381
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk